Gerresheimer: record year in 2007 and positive outlook for 2008

Düsseldorf (ots) -

- Cross reference: Key figures of the Fiscal Year are available at
http://www.presseportal.de/dokumente -

* Sales in 2007 increased by 48.1% to EUR957.7m
* Operating results (Adjusted EBITDA) up by 48.1% at EUR181.6m
* Proposed dividend: EUR0.40 per share
* CEO Dr. Axel Herberg: "For the financial year 2008 we expect
further sales growth, with an improved margin."

Gerresheimer AG has finished the financial year 2007 with record
figures in terms of sales and results. The company increased its
sales by 48.1% to EUR957.7m (2006: EUR646.7m). Excluding acquisition
and exchange-rate effects, Gerresheimer reports above-average sales
growth of 8.4%. Operating results (Adjusted EBITDA) rose by 48.1%
from EUR122.6m in the prior year to EUR181.6m. The company's
operating strength is shown by the Adjusted EBITDA margin of 19.0%.

The debt level before the IPO and the one-off costs of the IPO are
reflected in consolidated results of EUR0.8m (2006: EUR-25.0m). In
the fourth quarter, however, consolidated results already totalled
EUR13.9m, reaching a level which was no longer depressed by IPO costs
and for the first time reflected the company's low level of debt. The
adjusted consolidated results improved strongly during the financial
year to EUR44.3m (2006: EUR8.7m).

"We have achieved all the targets we set ourselves for 2007 and in
many cases exceeded them. For our company we look back over a very
successful financial year", says Dr. Axel Herberg, CEO of
Gerresheimer AG. Against the background of this brilliant business
development, the Management Board and the Supervisory Board will
propose to the Shareholders' Meeting that a dividend is already
distributed for the financial year of the IPO, which is to amount to
EUR0.40 per share.

Continuation of globalisation strategy

The strong growth of Gerresheimer AG is attributable on the one
hand to above-average organic growth and on the other hand to
acquisitions. The Wilden Group, which was acquired at the start of
2007 has already been fully integrated and made a sustained
contribution to the results of the Gerresheimer Group. Beyond this,
Gerresheimer also expanded its global presence through a number of
acquisitions and joint ventures. The company now operates in a
worldwide total of 41 locations and employs more than 10,800 people.

Positive development in all Divisions

Sales by the Tubular Glass Division in 2007 totalled EUR271.2m, up
11.4% on the prior year level of EUR243.4m. Adjusted EBITDA increased
to EUR66.7m (2006: EUR61.9m). A particularly strong contribution to
this growth was made by the 6% increase in sales of ready to fill
(RTF(r)) syringes. Through the commissioning of a second RTF(r)
syringe line, Gerresheimer has substantially expanded its production
capacity in order to meet the continuing high level of demand. A
third production line of this type is already in the planning stage
and is expected to be commissioned in 2009.

In 2007 the Plastic Systems Division achieved sales of EUR299.7m
compared with EUR48.2m in the prior year, and Adjusted EBITDA of
EUR56.1m (prior year: EUR12.0m). This improvement was largely
attributable to the acquisition of the Wilden Group, which during the
eleven months of its membership of the Gerresheimer Group made a
substantial contribution to the results of the Plastic Systems
Division. Growth in the core business of medical plastic systems was
particularly gratifying.

Increased sales of bottles for the pharmaceutical industry and of
perfume flacons and cream pots for the cosmetics industry resulted in
organic sales growth of 8.7% for the Moulded Glass Division. Overall
the Division achieved sales of EUR318.8m (2006: EUR299.4m) and a
19.7% rise in Adjusted EBITDA to EUR65.1m (prior year: EUR54.4m). The
marked margin improvement is attributable to consistent measures to
enhance productivity.

The joint venture entered into with Thermo Fisher Scientific in
mid-2007 meant that business in the Life Science Research Division
was substantially expanded. Sales by the Division rose by EUR29.4% to
EUR72.2m (prior year: EUR55.8m). Adjusted EBITDA improved to EUR7.7m
(prior year: EUR6.4m). Integration of the Chinese joint venture and
expansion of production in China are proceeding according to plan.
The competitive position of the Life Science Research division has
therefore been substantially strengthened.

Further growth in the financial year 2008

The new financial year for Gerresheimer AG started on 1 December
2007. CEO Dr. Axel Herberg believes that his management's strategies
have once more been confirmed: "As expected, we have had a successful
start to the year. In the highly specialised markets for packaging
and system solutions, Gerresheimer is widely recognised as a leading
global partner for the pharma & life science industry. I have no
doubt that in the current year we will be able not only to
consolidate our position but expand it intensively. We will continue
to grow."

On the basis of continuously increasing demand for special
packaging for the pharma & life science industry, Gerresheimer
expects a sales increase of between 13% and 15%. The Adjusted EBITDA
margin will, according to the target for the year, improve in
parallel beyond 19%. Planned investments in 2008 total EUR105-110m.

About Gerresheimer

Gerresheimer employs more than 10,800 people in 41 locations in
Europe, America and Asia. In the financial year 2007, worldwide sales
totalled EUR957.7m. The product portfolio ranges from pharmaceutical
vials made of glass and plastic through to complex drug-delivery
systems for the pharma & life science industry. These include sterile
syringes, inhalers and other system-based approaches for safe dosage
and application of medications. The Group enjoys a leading position
in markets which are characterised by high technical and regulatory
barriers.

Press Dates

Interim report 1st Quarter 2008 April 14, 2008
Annual General Meeting April 17, 2008
Interim report 2nd Quarter 2008 July 15, 2008
Interim report 3rd Quarter 2008 October 15, 2008
Annual financial statements 2008 February 17, 2009

Originaltext: Gerresheimer AG
digital press kits: http://www.presseportal.de/pm/9072
press kits via RSS: http://www.presseportal.de/rss/pm_9072.rss2
ISIN: DE0005873004

Contact Press
Burkhard Lingenberg
Director Corporate PR & Marketing
Telephone +49 211 6181-250
Telefax +49 211 6181-241
e-mail b.lingenberg@gerresheimer.com

Contact Investor Relations
Anke Linnartz
Director Corporate Investor
Telephone +49 211 6181 314
Telefax +49 211 6181 121
e-mail a.linnartz@gerresheimer.com